Metsera
Metsera raises $215M Series B at $1.2B valuation
Quick Facts
Metsera: Series B Funding Round
Metsera has successfully raised $215M in Series B funding, reaching a valuation of $1.2B.
Company Overview
Obesity and metabolic disease therapies
Funding Details
The Series B round was led by Venrock Healthcare Capital Partners, with participation from Wellington Management.
Company Information
- Headquarters: San Diego, CA
- Founded: 2022
- Employees: 100+
- Category: Biotech
Investment
Metsera plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Venrock Healthcare Capital Partners: Verified investor in Series B
- Wellington Management: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
